The rise of Large Language Models (LLMs) offers transfor-mative potential for interpreting complex legal frameworks, such as Title 18 Section 175 of the US Code, which governs biological weapons. These systems hold promise for advancing legal analysis and compliance monitoring in sensitive domains. However, this capability comes with a troubling contradiction: while LLMs can analyze and interpret laws, they also demonstrate alarming vulnerabilities in generating unsafe outputs, such as actionable steps for bioweapon creation, despite their safeguards. To address this challenge, we propose a methodology that integrates knowledge graph construction with Retrieval-Augmented Generation (RAG) to systematically evaluate LLMs' understanding of this law, their capacity to assess legal intent (mens rea), and their potential for unsafe applications. Through structured experiments, we assess their accuracy in identifying legal violations, generating prohibited instructions, and detecting unlawful intent in bioweapons-related scenarios. Our findings reveal significant limitations in LLMs' reasoning and safety mechanisms, but they also point the way forward. By combining enhanced safety protocols with more robust legal reasoning frameworks, this research lays the groundwork for developing LLMs that can ethically and securely assist in sensitive legal domains--ensuring they act as protectors of the law rather than inadvertent enablers of its violation.

Breakthroughs, discoveries, and DIY tips sent every weekday. Mosquito bites are much more than just a red and itchy summertime nuisance. The diseases that they carry are notoriously difficult to control and kill over 700,000 people worldwide every year. What's more, many mosquitoes have developed resistance to the synthetic insecticides–the same substances that can also pose environmental and health risks. As a solution, microbiologists are looking into biopesticides derived from living organisms.

In June of 2013, Elisabeth Bik, a microbiologist, grew curious about the subject of plagiarism. She had read that scientific dishonesty was a growing problem, and she idly wondered if her work might have been stolen by others. One day, she pasted a sentence from one of her scientific papers into the Google Scholar search engine. She found that several of her sentences had been copied, without permission, in an obscure online book. She pasted a few more sentences from the same book chapter into the search box, and discovered that some of them had been purloined from other scientists' writings.

AI is getting better and efficient every day. Now, it will help doctors better in cancer screenings and disease diagnoses. It can compete with human intelligence in one of the most highly skilled healthcare sectors. Have a glance over the mesmerizing work of'The Lancet Digital Health.' Researchers have presented a highly efficient algorithm with 98% sensitivity and 97% specificity to detect prostate cancer.

It can compete with human intelligence in one of the most highly skilled healthcare sectors. Have a glance over the mesmerizing work of'The Lancet …

Artificial intelligence is getting really, really good. In fact, it has become so technologically advanced that some high-skilled jobs that we once believed were "robot-proof" actually are not. The biomedical profession is ripe for overhaul. Consider a new paper in The Lancet Digital Health. Researchers developed an algorithm with 98% sensitivity and 97% specificity for detecting prostate cancer.

PERTH, Australia – There is pervasive use of artificial intelligence and machine learning (AI/ML) across the health care industry in Australia, and excitement is building on the opportunities it offers to technologies and ultimately to patients, Ausbiotech CEO Lorraine Chiroiu told BioWorld. "AI/ML is transforming clinical practice in terms of clinical trials, diagnosis, treatment, decision-making, early detection and preventative health," she said. AI is being used for everything from smart medical records to the systems that help set appointments, to hospital records and diagnostic and pathology tests. It's being used in diagnostics for cancer patients to redirect the best treatment regimens based on a number of patient variables, and patient records can be aggregated so that algorithms can narrow down diagnoses. AI is changing the precision around surgeries like knee replacements by using robotic surgery to diagnose the exact angles, Brandon Capital Managing Director Chris Nave told BioWorld.

In many laboratories, from clinical to pharmaceutical, there is a shortage of microbiologists trained in identification - the process of determining one genus or species of bacterium or fungus from another. Perhaps, Beth Israel Deaconess Medical Center researchers contend, artificial intelligence can address this shortfall. In the new research, the scientists have experimented with microscopes enhanced with artificial intelligence. These are designed to assist microbiologists diagnose microorganisms. The technology has been developed with the medical microbiology community in mind.

Artificial Intelligence is rapidly leaving its academic home and moving into the marketplace. There are few precedents for an arcane academic subject becoming commercialized so rapidly. But, genetic engineering, which recently burst forth from academia to become the foundation for the hot new biotechnology industry, provides useful insights into the rites of passage awaiting the commercializat,ion of artificial intelligence. This article examines the structural similarities and dissimilarities in the two subjects and briefly summarizes the history of the commercialization of genetic engineering. Within a few short years AI and genetic engineering have burst their academic restraints and are on the way to being commercialized by industry throughout the developed world.

Researchers at Beth Israel Deaconess Medical Center are using artificial intelligence to identify images of bacteria quickly and accurately through an AI-enhanced microscope, which they contend has the potential to alleviate the current national shortage of clinical microbiologists. BIDMC's Clinical Microbiology Laboratory is a "hidden part" of the Boston hospital, explains James Kirby, MD, director of the lab, but one that serves a critical function in diagnosing potentially deadly blood infections which is passed along to clinicians to determine appropriate therapies. "We have a microbiology technologist workforce, and one the things they spend a lot of time doing is looking at patient specimens in order to make a diagnosis of the type of infection people have," says Kirby, who is also associate professor of pathology at Harvard Medical School. It takes time, and it takes a lot of skill." However, Kirby notes that there is a nationwide shortage of highly trained microbiologists, ...